<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0186-4866</journal-id>
<journal-title><![CDATA[Medicina interna de México]]></journal-title>
<abbrev-journal-title><![CDATA[Med. interna Méx.]]></abbrev-journal-title>
<issn>0186-4866</issn>
<publisher>
<publisher-name><![CDATA[Edición y Farmacia S.A. de C.V.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0186-48662018000300015</article-id>
<article-id pub-id-type="doi">10.24245/mim.v34i3.1566</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Vasculitis reumatoidea como primera manifestación de artritis reumatoide]]></article-title>
<article-title xml:lang="en"><![CDATA[Rheumatoid vasculitis as first manifestation of rheumatoid arthritis]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Marín-Hernández]]></surname>
<given-names><![CDATA[Daniela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Orrantia-Vértiz]]></surname>
<given-names><![CDATA[Mauricio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barragán-Garfias]]></surname>
<given-names><![CDATA[Jorge Alberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Duarte-Mote]]></surname>
<given-names><![CDATA[Jesús]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Español de México  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Español de México  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<aff id="Af3">
<institution><![CDATA[,IMSS  ]]></institution>
<addr-line><![CDATA[Toluca Estado de México]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2018</year>
</pub-date>
<volume>34</volume>
<numero>3</numero>
<fpage>480</fpage>
<lpage>485</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0186-48662018000300015&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0186-48662018000300015&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0186-48662018000300015&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La vasculitis reumatoidea es la complicación extraarticular más grave de la artritis reumatoide, con morbilidad y mortalidad altas. Se trata de un proceso inflamatorio que afecta principalmente los vasos sanguíneos de pequeño y mediano calibre, sus manifestaciones clínicas sobrevienen de forma heterogénea, la vasculitis cutánea y la neuropatía son las más comunes. Su incidencia ha disminuido en las últimas décadas debido a la administración temprana de fármacos modificadores de la enfermedad en la artritis reumatoide. A pesar de la administración de ciclofosfamida y la existencia de medicamentos biológicos, continúa siendo un reto lograr el control de la enfermedad. Comunicamos el caso de un paciente de 50 años de edad, sin antecedentes médicos de importancia, salvo tabaquismo, que inició con neuropatía secundaria a vasculitis con factor reumatoide y anticuerpos antipéptido cíclico citrulinado positivos. La revisión bibliográfica pone al día los conocimientos acerca de la enfermedad para considerarla diagnóstico diferencial.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract The rheumatoid vasculitis is the most serious complication of rheumatoid arthritis, with high morbidity and mortality. It is an inflammatory process that affects small and medium vessels and that has heterogeneous manifestations, being the cutaneous lesions and neuropathy the most common. Its incidence has declined in the last decades because of the early use of disease modifying antirheumatic drugs. Despite the use of cyclophosphamide and the existence of biologic drugs, achieving the control of the disease continues to be a challenge. We present the case of a 50 year-old man, without relevant antecedents, only tabaco use, that presented with a vasculitic neuropathy, rheumatoid factor and cyclic citrullinated peptide antibody positive. This bibliographic review has the intention to update the knowledge of this entity and to be considered a differential diagnosis.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Vasculitis reumatoidea]]></kwd>
<kwd lng="es"><![CDATA[artritis reumatoide]]></kwd>
<kwd lng="es"><![CDATA[vasculitis]]></kwd>
<kwd lng="en"><![CDATA[Rheumatoid vasculitis]]></kwd>
<kwd lng="en"><![CDATA[Rheumatoid arthritis]]></kwd>
<kwd lng="en"><![CDATA[Vasculitis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bartels]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatoid vasculitis Vanishing menace or target for new treatments?]]></article-title>
<source><![CDATA[Curr Rheumatol Rep]]></source>
<year>2010</year>
<volume>12</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>414-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lanzillo]]></surname>
<given-names><![CDATA[BPN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subclinical peripheral nerve involvement in patients with rheumatoid arthritis]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>1998</year>
<volume>41</volume>
<page-range>1196-202</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turesson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of HLA-C3 and Smoking with vasculitis in patients with rheumatoid arthritis]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>2006</year>
<volume>54</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2776-83</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laskaria]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Are anti-cyclic citrullinated peptide autoantibodies seromarkers for rheumatoid vasculitis in a cohort of patients with systemic vasculitis]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2010</year>
<volume>69</volume>
<page-range>469-71</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Voskuyl]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic strategy for the assessment of rheumatoid vasculitis]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2003</year>
<volume>62</volume>
<page-range>407-13</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Makol]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Matteson]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatoid vasculitis an update]]></article-title>
<source><![CDATA[Curr Opin Rheumatol]]></source>
<year>2015</year>
<numero>1</numero>
<issue>1</issue>
<page-range>63-70</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ntatsaki]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2014</year>
<volume>53</volume>
<page-range>145-52</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Genta]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic rheumatoid vasculitis a review]]></article-title>
<source><![CDATA[Semin Arthr Rheum]]></source>
<year>2006</year>
<volume>36</volume>
<page-range>88-98</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hellmann]]></surname>
<given-names><![CDATA[MJN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Successful treatment of rheumatoid vasculitis-associated cutaneous ulcers using rituximab in two patients with rheumatoid arthritis]]></article-title>
<source><![CDATA[Rheumatology (Oxford)]]></source>
<year>2008</year>
<volume>47</volume>
<page-range>929-30</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gorman]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Particular HLA-DRB1 Shared Epitope Genotypes Are Strongly Associated With Rheumatoid Vasculitis]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>2004</year>
<volume>50</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>3476-84</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaye]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The frequency of cutaneous vasculitis is not increased in patients with rheumatoid arthritis treated with methotrexate]]></article-title>
<source><![CDATA[J Rheumatol]]></source>
<year>1996</year>
<volume>23</volume>
<page-range>253-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and histopathological spectrum of cutaneous vasculitis in rheumatoid arthritis]]></article-title>
<source><![CDATA[Br J Dermatol]]></source>
<year>2002</year>
<volume>147</volume>
<page-range>905-13</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cojocaru]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New insight into the rheumatoid vasculitis]]></article-title>
<source><![CDATA[Romanian J Inl Med]]></source>
<year>2015</year>
<volume>53</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>128-32</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maher]]></surname>
<given-names><![CDATA[LV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Successful treatment of rheumatoid vasculitis-associated foot drop with rituximab]]></article-title>
<source><![CDATA[Rheumatology (Oxford)]]></source>
<year>2006</year>
<volume>45</volume>
<page-range>1450-1</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Genta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic rheumatoid vasculitis A review]]></article-title>
<source><![CDATA[Semin Arthr Rheum]]></source>
<year>2006</year>
<volume>36</volume>
<page-range>88-98</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chadha]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Burning vasculitis]]></article-title>
<source><![CDATA[Br Med J Case Reports]]></source>
<year>2016</year>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Puechal]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antitumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2008</year>
<volume>67</volume>
<page-range>880-4</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Bacon]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>1984</year>
<volume>76</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>377-84</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic rheumatoid vasculitis a clinical and laboratory study of 50 cases]]></article-title>
<source><![CDATA[Medicine (Baltimore)]]></source>
<year>1981</year>
<volume>60</volume>
<page-range>288-97</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[DGI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IgG rheumatoid factor, complement and immune complexes in rheumatoid synovitis andvasculitis comparative and serial studies during cytotoxic therapy]]></article-title>
<source><![CDATA[J Clin Exp Immunol]]></source>
<year>1981</year>
<volume>43</volume>
<page-range>54-6</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Voskuyl]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors associated with the development of vasculitis in rheumatoid arthritis results of a case-control study]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>1996</year>
<volume>55</volume>
<page-range>190-2</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Watts]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatoid vasculitis becoming extinct?]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2004</year>
<volume>43</volume>
<page-range>920-3</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Puéchal]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Associated with rheumatoid arthritis results from the AutoImmunity and Rituximab Registry]]></article-title>
<source><![CDATA[Arthritis Care Res]]></source>
<year>2012</year>
<volume>64</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>331-9</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Puéchal]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>1995</year>
<volume>38</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1618-29</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
